Ketamine and Esketamine for Bipolar Depression
February 27, 2025 DOI: 10.64239/pi-qt7204 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Review |
|---|---|
| Population | Patients with bipolar depression |
| Interventions | Ketamine Esketamine |
| Topics | Depression Esketamine Ketamine |
| Key findings | Ketamine and esketamine show promise for bipolar depression with a 40% response rate and 13% full remission, but 30% of patients experienced hypomania or mania during maintenance treatment. |
Abstract
Ketamine and esketamine show promise in bipolar depression, with 40% of patients responding to twice-weekly treatment. Full remission occurs in 13%. No immediate manic switches occurred during intensive treatment, but 30% experienced hypomania/mania during maintenance phase. Most episodes were mild. Consider involving family members in monitoring mood changes. Patients with severe mania or rapid cycling history may not be ideal candidates.